Resistance to Immunotherapeutic Antibodies in Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Resistance to Immunotherapeutic Antibodies in Cancer PDF full book. Access full book title Resistance to Immunotherapeutic Antibodies in Cancer by Benjamin Bonavida. Download full books in PDF and EPUB format.
Author: Benjamin Bonavida
Publisher: Springer Science & Business Media
ISBN: 1461476542
Category : Medical
Languages : en
Pages : 210
Get Book Here
Book Description
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Author: Benjamin Bonavida
Publisher: Springer Science & Business Media
ISBN: 1461476542
Category : Medical
Languages : en
Pages : 210
Get Book Here
Book Description
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Author: Jorge Morales Montor
Publisher: Academic Press
ISBN: 0128220295
Category : Science
Languages : en
Pages : 288
Get Book Here
Book Description
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
Author: Benjamin Bonavida
Publisher: Springer
ISBN: 3319178075
Category : Medical
Languages : en
Pages : 364
Get Book Here
Book Description
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.
Author: Macfarlane Burnet
Publisher: Elsevier
ISBN: 1483159221
Category : Medical
Languages : en
Pages : 289
Get Book Here
Book Description
Immunological Surveillance
Author: Laurence Zitvogel
Publisher: Springer
ISBN: 3319624318
Category : Medical
Languages : en
Pages : 700
Get Book Here
Book Description
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
Author: Lin Qi
Publisher: Frontiers Media SA
ISBN: 2832544894
Category : Science
Languages : en
Pages : 215
Get Book Here
Book Description
The adaptive immune resistance (AIR) mechanism refers to the various strategies employed by tumours to adapt and ultimately to overcome immune attack. The AIR mechanism was firstly identified in the selective induction of programmed cell death 1 ligand 1 (PDL1) by interferon gamma of tumors. The inhibition of adaptive immune resistance underlies the responses to PD-1 or PD-L1–blocking antibodies, and may have relevance for the development of other cancer immunotherapy strategies. Therefore, identifying specific AIR mechanisms is of great significance to develop novel drugs and enhance the efficacy of cancer treatment. In this research topic, we aim to generate a collection of articles that discuss the AIR mechanisms, the classification of AIRs, and the current and future cancer therapy strategies based on AIR. Of particular, these articles can focus on exploring the AIR mechanisms in different cancer types and further identify the association between AIR and tumour microenvironment (TME).
Author: Mansoor M. Amiji
Publisher: Elsevier
ISBN: 0128233974
Category : Business & Economics
Languages : en
Pages : 548
Get Book Here
Book Description
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO
Author: Morten Hansen
Publisher: Frontiers Media SA
ISBN: 2889764419
Category : Medical
Languages : en
Pages : 470
Get Book Here
Book Description
Dr. Koguchi receives funding from Tesaro, a GSK company, Bristol-Myers Squibb, and Shimadzu Corporation.. Dr. Vujanovic is a co-inventor of a methodology licensed to INmune Bio, Inc. where a selective inhibitor of soluble TNF can be used to prevent or treat malignancies. Dr. Hansen is the recipient of a private grant from Eurostars Eureka. The other Topic Editors declare no competing interests.
Author: Lisa H. Butterfield, PhD
Publisher: Springer Publishing Company
ISBN: 0826137431
Category : Medical
Languages : en
Pages : 1339
Get Book Here
Book Description
Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs
Author: Subree Subramanian
Publisher: Mdpi AG
ISBN: 9783036587028
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
In recent years, cancer immunotherapy has made remarkable progress, revolutionizing cancer treatment. Our Special Issue "Cancer Immunology" in the journal Cancers showcased cutting-edge research and reviews. Building on that success, this new Special Issue explores recent advancements, technologies, and future prospects in cancer immunology, pre-clinical assessments, and clinical trials. While immune checkpoint inhibitors have been transformative, addressing limited response remains crucial. Strategies to overcome resistance, such as combination therapies and targeted pathways, are discussed in the issue. Chimeric antigen receptor (CAR) T cell therapy is an important area of immunotherapy, with exciting findings for enhancing CAR persistence and efficacy. Conventional treatments and monoclonal antibodies also activate immunological mechanisms, boosting cytotoxic efficacy against specific cancers. Identifying biomarkers associated with treatment response is vital for personalized cancer immunotherapy. Potential biomarkers like immune cell densities and estrogen receptor expression are explored in this Issue. The review articles cover advancements in CAR T cell therapy, tumor metabolic alterations, immune suppressive cells, and the role of bacteria in cancer immunotherapy. This Special Issue is a valuable resource for researchers, clinicians, and industry professionals, guiding future developments towards more effective and personalized cancer immunotherapies.